ISLAMABAD: Pakistan’s BF Biosciences Limited, a subsidiary of Ferozsons Laboratories Limited, has launched its new product Zeptide® (Tirzepatide) for the treatment of type 2 diabetes and obesity, the company said in a filing to the Pakistan Stock Exchange (PSX) this month.
The launch comes as Pakistan faces one of the world’s highest diabetes burdens, affecting over 33 million adults, which is about 26 percent of the adult population. The country ranks third globally in the absolute number of people with diabetes and faces a growing crisis as nine million people remain undiagnosed. According to the World Health Organization, 57 percent of women and 41 percent of men in the country are overweight or obese, with obesity increasing the risk of Type 2 diabetes by 7 times.
“Tirzepatide is a synthetic polypeptide molecule that acts as a dual agonist for the GLP-1 and GIP receptors, meaning it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor pathways,” the company said in a listing earlier this month.
BF Biosciences said Zeptide, approved by the US Food and Drug Administration (FDA), is produced at its new state-of-the-art European prefilled-syringes facility.
